Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a monthly compilation of research articles funded by AHRQ or authored by AHRQ researchers and recently published in journals or newsletters.
Results1 to 2 of 2 Research Studies Displayed
Maloney MH, Payne SR, Herrin J
Risk of systemic adverse events after intravitreal bevacizumab, ranibizumab, and aflibercept in routine clinical practice.
Intravitreal anti-vascular endothelial growth factor (VEGF) pharmacotherapy plays a central role in the management of neovascular age-related macular degeneration (nAMD), diabetic retinal disease (DRD), and retinal venous occlusive disease (RVO). The goal of this study was to compare the systemic safety of intravitreal bevacizumab, ranibizumab, and aflibercept in real-world practice. The investigators observed no differences in the risk of acute MI, CVD, major bleeding, or all-cause hospitalization after treatment initiation with intravitreal bevacizumab, ranibizumab, or aflibercept during routine clinical practice.
AHRQ-funded; HS024075; HS025164; HS025402; HS025517; HS026379.
Citation: Maloney MH, Payne SR, Herrin J . Risk of systemic adverse events after intravitreal bevacizumab, ranibizumab, and aflibercept in routine clinical practice. Ophthalmology 2021 Mar;128(3):417-24. doi: 10.1016/j.ophtha.2020.07.062..
Keywords: Eye Disease and Health, Medication, Risk, Adverse Drug Events (ADE), Adverse Events
Gopal AD, Wallach JD, Shah SA
On-label and off-label clinical studies of FDA-approved ophthalmic therapeutics.
The authors characterized the frequency, accrual, and quality of on-label and off-label prospective studies of novel FDA-approved ophthalmic therapeutics. They concluded that ophthalmologists should recognize that, for some therapeutics, prospective data guiding off-label use may be limited; expanding post-approval evaluation of FDA-approved and off-label indications may mitigate uncertainties and aid ophthalmologists in optimally assessing the decision to adopt approved therapeutics for off-label use.
AHRQ-funded; HS025164; HS022882.
Citation: Gopal AD, Wallach JD, Shah SA . On-label and off-label clinical studies of FDA-approved ophthalmic therapeutics. Ophthalmology 2021 Feb;128(2):332-34. doi: 10.1016/j.ophtha.2020.07.028..
Keywords: Medication, Eye Disease and Health